Ramantamig not checked
Johnson & Johnson (Janssen) · JNJ-79635322 · BCMAxGPRC5DxCD3
FollowEvery change as it happens, and a Monday email
Trials
9 active
9 in total · 6 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
- How it’s given
- “Ramantamig will be administered as subcutaneous (SC) injection.”In the company’s words, NCT07903272 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma (8 trials), Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
- Main trialPhase 3
- “The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.”In the company’s words, NCT07258511 on ClinicalTrials.gov
- Other names
- JNJ-79635322 · BCMAxGPRC5DxCD3
Other drugs for Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up9
- 19 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 14 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 12 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 2 Jan 2029Phase 1 trial completes · ClinicalTrials.gov
- 29 Apr 2029Phase 3 trial completes · ClinicalTrials.gov
- 30 May 2030Phase 2 trial completes · ClinicalTrials.gov
- 4 Sep 2030Phase 3 trial completes · ClinicalTrials.gov
- 11 Jan 2037Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 12 Dec 2028 | A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 3Recruiting | 29 Apr 2029 | A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 3Recruiting | 4 Sep 2030 | A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned | |
| Phase 3Not yet recruiting | 11 Jan 2037 | A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible | |
| Phase 2Active, not recruiting | 14 Jun 2027 | A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 2Recruiting | 31 Dec 2027 | A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma | |
| Phase 2Recruiting | 30 May 2030 | A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events | |
| Phase 1Recruiting | 19 Apr 2027 | A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | |
| Phase 1Recruiting | 2 Jan 2029 | A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026